Molecular Targets of Mesalazine in Colorectal Cancer

Author(s): Carmine Stolfi, Roberto Pellegrini, Francesco Pallone, Giovanni Monteleone

Journal Name: Current Cancer Therapy Reviews

Volume 4 , Issue 4 , 2008

Become EABM
Become Reviewer


Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD). Although conclusive evidence is still missing, epidemiological and preliminary clinical work strongly suggests that mesalazine may have chemopreventive properties against IBD-related CRC. Therefore, in recent years, several experimental studies have been conducted to dissect the mechanism(s) by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular pathways that are regulated by mesalazine in CRC.

Keywords: Colorectal cancer (CRC), inflammatory bowel disease (IBD), mesalazine, molecular pathways, EGFR

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [262 - 266]
Pages: 5
DOI: 10.2174/157339408786413326
Price: $65

Article Metrics

PDF: 3